**Specifications Table**TableSubject area*Biology*More specific subject area*Reproductive Biology*Type of data*Tables, graphs*How data was acquired*Collected empirical data, RNA microarray, Ingenuity Pathway Analysis, Panther Database*Data format*Raw data; Normalized, analyzed, and filtered data; curated bioinformatics predictions*Experimental factors*The estrous cycles of cows were synchronized using two injections of 25* *mg Lutalyse 11 days apart.*Experimental features*Post-pubertal multiparous female cattle (n = 16) of composite breeding were treated by intramuscular injection at midcycle (days 9--10) with saline (n = 4) or PGF2α (n = 12) (25* *mg Lutalyse). RNA was isolated from the corpus luteum and analyzed by microarray. Differentially expressed transcripts were subjected to bioinformatics pathway analysis.*Data source location*Lincoln, NE, USA; Omaha, NE, USA*Data accessibility*Raw data is in the public NCBI repository GEO (*GSE94069)*, curated bioinformatics predictions are presented within the article as tables*

Value of the data {#s0005}
=================

•This study provides the first transcriptomics analysis of the early time-course (0.5--4 h) of the response to prostaglandin F2 α (PGF2α) and extends previous observations on the global effects of PGF2α action in the bovine corpus luteum at 3 h and longer [@bib2], [@bib3].•Prediction of upstream regulators and regulation of canonical pathways based on the transcriptome changes during the PGF2α short time-course.•A complete list of differentially expressed transcripts grouped into self-organizing maps representative of signaling waves after PGF2α treatment.•Canonical pathways and upstream regulators predicted by Ingenuity Pathway Analysis for genes common to three similar datasets [@bib1], [@bib2], [@bib3].

1. Data {#s0010}
=======

•The .cel and .chp files and normalized linear microarray data are available at the NCBI GEO repository: GSE94069•[Fig. 1](#f0005){ref-type="fig"} -- Functional categorization of differentially expressed transcripts throughout the PGF2α time-courseFig. 1Biological process annotation of differentially expressed genes from each time point. **(A)** Percent of mapped genes with "transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding" or "protein binding" annotations based on DAVID molecular function analysis (GOTERM_MF_ALL) of all differentially expressed genes from each time point. **(B)** Percent of mapped genes with "transcription factor (PC00218)", "hydrolase (PC00121)", or "transferase (PC00220)" annotations based on Panther Protein Class analysis of differentially expressed genes from each time point.Fig. 1•[Fig. 2](#f0010){ref-type="fig"} -- Empirical characteristics of the female cattle used in the studyFig. 2Physiological characteristics of the study animals. Mid-cycle cows were treated with 25 mg PGF2α for 0.5, 1, 2, and 4 h (n = 3/time point) or saline (n = 4). Symbols indicate individuals or each ovary, with mean±SD overlaid. **(A)** Age (in years) of cows at ovariectomy. **(B)** Number of antral follicles present on each ovary from study animals. **(C)** Total weight of each ovary from study animals. **(D)** Weight of corpus luteum (CL) from each study animal. **(E)** Previous number of calves from each study animal. **(F)** Serum progesterone concentrations of cows 0.5--4 h post-PGF2α treatment \* *P* ≤ 0.05, \*\* *P* ≤ 0.01 compared to saline-treated animals using one-way ANOVA followed by Bonferroni\'s multiple comparison test.Fig. 2•[Table 1](#t0005){ref-type="table"} -- Ingenuity Pathway Analysis predicted canonical pathways involved during the PGF2α time-courseTable 1Canonical pathways of PGF2α time course [⁎](#tbl1fnStar){ref-type="table-fn"}.Table 1**0.5** **h1** **h2** **h4** **hIngenuity Canonical Pathwaysz-score*****P-value (B-H)*****z-score*****P-value (B-H)*****z-score*****P-value (B-H)*****z-score*****P-value (B-H)*****\|Avg.\| z-score**Death Receptor Signaling−2.713.23E-010.90Integrin Signaling−2.684.69E-010.89UVA-Induced MAPK Signaling2.51E-022.65E-017.96E-01−2.501.64E-010.83MIF Regulation of Innate Immunity1.58E-028.71E-026.44E-012.453.44E-010.82Retinoic acid Mediated Apoptosis Signaling4.81E-01−2.451.78E-010.82Melanocyte Development and Pigmentation Signaling−2.321.64E-010.77TREM1 Signaling7.89E-012.311.10E-010.77CREB Signaling in Neurons−2.184.61E-010.73Aldosterone Signaling in Epithelial Cells4.37E-027.76E-024.89E-01−2.149.55E-020.71NGF Signaling8.39E-01−2.134.79E-020.71Calcium Signaling−2.112.64E-010.53Toll-like Receptor Signaling2.24E-026.61E-022.002.99E-012.142.69E-021.03ILK Signaling5.25E-022.452.34E-021.637.31E-011.60E-011.36Inflammasome pathway7.55E-012.002.98E-010.50MIF-mediated Glucocorticoid Regulation2.005.16E-010.50JAK/Stat Signaling2.24E-022.45E-023.49E-01−2.008.32E-020.50Granzyme B Signaling7.43E-01−2.002.30E-010.50Dopamine-DARPP32 Feedback in cAMP Signaling6.15E-01−2.004.50E-010.50Signaling by Rho Family GTPases7.59E-022.001.61E-010.67LPS/IL-1 Mediated Inhibition of RXR Function2.57E-012.007.43E-011.905.79E-010.97LXR/RXR Activation−1.344.99E-01−2.321.61E-010.92Cholecystokinin/Gastrin-mediated Signaling2.45E-022.003.89E-022.652.99E-010.696.76E-021.33TGF-β Signaling2.24E-027.76E-022.005.45E-011.161.66E-010.79Acute Phase Response Signaling4.37E-021.007.76E-022.124.81E-011.531.23E-011.16HMGB1 Signaling3.09E-022.002.45E-021.893.44E-010.691.34E-011.14Gαq Signaling6.41E-01−0.457.46E-01−2.073.13E-010.63Colorectal Cancer Metastasis Signaling7.41E-022.001.61E-011.137.52E-01−0.382.59E-010.69Endothelin-1 Signaling4.90E-022.008.71E-02−0.663.94E-010.34PI3K Signaling in B Lymphocytes1.41E-021.22E-011.344.81E-01−0.212.69E-020.28Corticotropin Releasing Hormone Signaling1.41E-023.89E-026.43E-01−0.542.00E-010.18IL-8 Signaling5.62E-022.001.08E-010.458.39E-01−1.094.00E-010.34NRF2-mediated Oxidative Stress Response1.41E-020.451.00E-020.381.75E-010.241.11E-010.27Cardiac Hypertrophy Signaling2.86E-012.88E-011.637.99E-01−2.041.71E-010.10IGF-1 Signaling1.41E-021.001.91E-020.822.41E-01−1.298.51E-020.13IL-17A Signaling in Gastric Cells1.41E-026.61E-024.99E-016.10E-01[^3]•[Table 2](#t0010){ref-type="table"} -- Ingenuity Pathway Analysis predicted canonical pathways for the dataset comparisonTable 2Canonical pathways of dataset comparison [⁎](#tbl2fnStar){ref-type="table-fn"}.Table 2**GSE94069GSE23348GSE27961Ingenuity Canonical Pathwaysz-score*****P-value (B-H)*****z-score*****P-value (B-H)*****z-score*****P-value (B-H)*****\|Avg.\| z-score**TREM1 Signaling2.311.90E-014.243.55E-012.244.34E-012.93p38 MAPK Signaling1.347.94E-013.361.66E-012.531.75E-012.41Acute Phase Response Signaling1.531.19E-013.582.19E-012.126.24E-012.41Dendritic Cell Maturation1.13E-013.272.90E-011.415.18E-012.34Inflammasome pathway2.003.20E-012.655.13E-015.10E-012.33MIF Regulation of Innate Immunity2.453.52E-012.002.67E-012.23CREB Signaling in Neurons−2.184.67E-012.18LPS/IL-1 Mediated Inhibition of RXR Function1.905.85E-012.451.80E-012.26E-012.18Role of IL-17F in Allergic Inflammatory Airway Diseases1.274.68E-013.001.20E-012.241.35E-012.17LXR/RXR Activation−2.321.17E-01−2.831.35E-01−1.344.28E-012.16Aldosterone Signaling in Epithelial Cells−2.149.12E-011.75E-014.99E-012.14Type I Diabetes Mellitus Signaling6.11E-012.114.70E-012.11IL-6 Signaling1.232.57E-013.412.75E-011.673.27E-012.10MIF-mediated Glucocorticoid Regulation2.005.18E-012.001.61E-012.00Granzyme B Signaling−2.002.32E-016.98E-017.60E-012.00Dopamine-DARPP32 Feedback in cAMP Signaling−2.004.62E-012.00Role of Wnt/GSK-3β Signaling in the Pathogenesis of Influenza2.005.10E-012.00Toll-like Receptor Signaling2.142.57E-012.715.62E-011.006.24E-011.95PI3K/AKT Signaling2.132.57E-011.906.92E-011.673.83E-011.90Actin Nucleation by ARP-WASP Complex1.631.58E-012.005.10E-011.82ILK Signaling1.53E-012.325.25E-011.291.59E-011.81Retinoic acid Mediated Apoptosis Signaling−2.451.74E-01-1.001.61E-017.26E-011.73HMGB1 Signaling0.451.90E-012.992.82E-011.673.45E-011.70Regulation of Actin-based Motility by Rho1.345.77E-012.007.60E-011.67Rac Signaling4.67E-012.141.70E-011.135.31E-011.64Cholecystokinin/Gastrin-mediated Signaling0.697.80E-012.312.57E-011.894.75E-011.63VDR/RXR Activation0.821.19E-011.672.34E-012.242.82E-011.58NF-κB Signaling0.542.57E-013.272.75E-010.914.34E-011.57iNOS Signaling1.001.14E-012.003.21E-011.50Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses−0.281.66E-013.214.37E-014.84E-011.47Ephrin Receptor Signaling0.823.93E-012.005.85E-011.41Agrin Interactions at Neuromuscular Junction0.385.27E-012.005.86E-011.631.59E-011.34Tec Kinase Signaling−1.215.31E-013.507.80E-011.416.59E-011.23ERK5 Signaling0.288.32E-011.415.75E-012.005.51E-011.23Production of Nitric Oxide and Reactive Oxygen Species in Macrophages−0.761.90E-013.153.39E-011.20UVA-Induced MAPK Signaling−2.671.19E-011.90E-010.455.51E-011.11PI3K Signaling in B Lymphocytes−0.212.57E-012.365.13E-011.08Colorectal Cancer Metastasis Signaling−0.562.18E-012.707.80E-011.003.70E-011.05Basal Cell Carcinoma Signaling−0.456.34E-012.453.70E-011.00B Cell Receptor Signaling−0.589.77E-012.838.71E-010.716.50E-010.99Phospholipase C Signaling−1.414.62E-013.325.32E-011.005.10E-010.97Glioma Invasiveness Signaling−0.302.69E-012.118.32E-011.001.38E-010.94Oncostatin M Signaling−0.454.23E-012.249.12E-014.95E-010.90Neuregulin Signaling−0.303.13E-012.005.81E-017.60E-010.85JAK/Stat Signaling−2.007.94E-010.338.32E-010.84Calcium Signaling−2.112.77E-010.451.38E-010.83Role of RIG1-like Receptors in Antiviral Innate Immunity−0.451.90E-012.005.75E-010.78Type II Diabetes Mellitus Signaling−0.583.36E-012.122.23E-010.77PKCθ Signaling in T Lymphocytes−1.411.66E-012.503.72E-010.55NGF Signaling−2.135.10E-012.332.85E-011.346.32E-010.51Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes−1.733.97E-012.122.31E-011.134.28E-010.51Role of NFAT in Regulation of the Immune Response−1.503.75E-012.506.92E-010.50Cardiac Hypertrophy Signaling−2.401.69E-011.704.00E-012.144.34E-010.48Death Receptor Signaling−2.713.36E-010.283.89E-011.007.24E-010.48Wnt/Ca+ pathway−1.134.67E-010.452.92E-012.005.10E-010.44Gαq Signaling−2.364.40E-011.512.39E-010.43CNTF Signaling−2.111.33E-011.343.51E-015.26E-010.39IL-8 Signaling−1.904.19E-012.005.10E-010.584.70E-010.23Integrin Signaling−2.684.88E-011.514.99E-011.394.34E-010.07Melanocyte Development and Pigmentation Signaling−2.321.56E-011.344.90E-010.824.34E-010.05[^4]•[Table 3](#t0015){ref-type="table"} -- Ingenuity Pathway Analysis predicted canonical pathways for the genes common to all datasetsTable 3Canonical pathways of common genes [⁎](#tbl3fnStar){ref-type="table-fn"}.Table 3**Ingenuity Canonical Pathwaysz-score*****P*****-valueMolecules**Glioma Invasiveness Signaling2.001.74E-03*PIK3CA, ITGAV, PLAUR, CD44*IL-6 Signaling2.002.00E-03*IL18, PIK3CA, SRF, CD14, IL33*Acute Phase Response Signaling2.002.57E-02*IL18, PIK3CA, SERPINE1, IL33*NF-κB Signaling2.003.16E-02*IL18, PIK3CA, BMP2, IL33*PDGF Signaling1.003.63E-03*PIK3CA, SRF, SPHK1, PDGFC*LXR/RXR Activation−1.007.41E-03*IL18, CD14, ARG2, IL33*Atherosclerosis Signaling1.05E-03*IL18, TNFRSF12A, MMP1, IL33, PDGFC*HIF1α Signaling1.07E-03*PIK3CA, LDHA, SLC2A1, MMP1, PDGFC*GDP-glucose Biosynthesis1.10E-03*HK2, PGM5*IL-10 Signaling1.23E-03*IL18, CD14, ARG2, IL33*Hepatic Fibrosis / Hepatic Stellate Cell Activation1.29E-03*BAMBI, CD14, SERPINE1, AGTR1, MMP1, PDGFC*Glucose and Glucose-1-phosphate Degradation1.45E-03*HK2, PGM5*Bladder Cancer Signaling2.34E-03*CDKN1A, THBS1, MMP1, PDGFC*Human Embryonic Stem Cell Pluripotency2.57E-03*INHBA, PIK3CA, SPHK1, BMP2, PDGFC*TGF-β Signaling3.24E-03*INHBA, TGIF1, SERPINE1, BMP2*Granulocyte Adhesion and Diapedesis3.80E-03*IL18, SDC4, CLDN1, MMP1, IL33*Agranulocyte Adhesion and Diapedesis4.79E-03*IL18, SDC4, CLDN1, MMP1, IL33*Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis4.79E-03*IL18, PIK3CA, BMP2, SPP1, MMP1, IL33*Role of Tissue Factor in Cancer1.07E-02*PIK3CA, ITGAV, PLAUR, MMP1*LPS/IL-1 Mediated Inhibition of RXR Function1.12E-02*IL18, CD14, HS3ST5, NR5A2, IL33*VDR/RXR Activation1.41E-02*CD14, CDKN1A, SPP1*Altered T Cell and B Cell Signaling in Rheumatoid Arthritis1.41E-02*IL18, SPP1, IL33*Palmitate Biosynthesis I (Animals)1.45E-02*OXSM*Fatty Acid Biosynthesis Initiation II1.45E-02*OXSM*Toll-like Receptor Signaling1.48E-02*IL18, CD14, IL33*Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza1.78E-02*IL18, IL33*Graft-versus-Host Disease Signaling1.91E-02*IL18, IL33*Macropinocytosis Signaling1.95E-02*PIK3CA, CD14, PDGFC*Hepatic Cholestasis2.00E-02*IL18, CD14, NR5A2, IL33*[^5]•[Table 4](#t0020){ref-type="table"} -- Comparison of bioinformatics tool predictions for the genes common to all datasetsTable 4Comparison of bioinformatic tools ^⁎^.Table 4**DAVID (124/124)IPA (116/124)Panther (94/124)String (93/124)Canonical Pathways*****P*****-value*****P*****-value*****P*****-valueFalse Discovery Rate**TGF-beta signaling pathway5.20E-033.24E-032.21E-022.94E-02p53 signaling pathway2.20E-023.89E-022.26E-02Proteoglycans in cancer1.50E-038.24E-03HIF-1 signaling pathway9.50E-031.07E-03ECM-receptor interaction6.10E-038.24E-03Bladder cancer4.50E-022.34E-03Atherosclerosis Signaling1.05E-03GDP-glucose Biosynthesis1.10E-03IL-10 Signaling1.23E-03Hepatic Fibrosis/Hepatic Stellate Cell Activation1.29E-03Glucose and Glucose-1-phosphate Degradation1.45E-03Glioma Invasiveness Signaling1.74E-03Human Embryonic Stem Cell Pluripotency2.57E-03PDGF Signaling3.63E-03Granulocyte Adhesion and Diapedesis3.80E-03Agranulocyte Adhesion and Diapedesis4.79E-03Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis4.79E-03Plasminogen activating cascade7.05E-03LXR/RXR Activation7.41E-03Role of Tissue Factor in Cancer1.07E-02LPS/IL-1 Mediated Inhibition of RXR Function1.12E-02VDR/RXR Activation1.41E-02Altered T Cell and B Cell Signaling in Rheumatoid Arthritis1.41E-02Palmitate Biosynthesis I (Animals)1.45E-02Fatty Acid Biosynthesis Initiation II1.45E-02Toll-like Receptor Signaling1.48E-02Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza1.78E-02Graft-versus-Host Disease Signaling1.91E-02Macropinocytosis Signaling1.95E-02Hepatic Cholestasis2.00E-02Coagulation System2.40E-02LPS-stimulated MAPK Signaling2.45E-02PPAR Signaling2.45E-02Acute Phase Response Signaling2.57E-02HER-2 Signaling in Breast Cancer2.57E-02RNA degradation2.60E-02Role of Cytokines in Mediating Communication between Immune Cells2.69E-02Prostate Cancer Signaling2.75E-02Aldosterone Signaling in Epithelial Cells2.75E-02Trehalose Degradation II (Trehalase)2.88E-02Pyruvate Fermentation to Lactate2.88E-02Arginine Degradation I (Arginase Pathway)2.88E-02NF-κB Signaling3.16E-02tRNA Splicing3.16E-02Cholecystokinin/Gastrin-mediated Signaling3.31E-02Role of Oct4 in Mammalian Embryonic Stem Cell Pluripotency3.80E-02Glucocorticoid Receptor Signaling3.98E-02Nitric Oxide Signaling in the Cardiovascular System3.98E-02Glioma Signaling4.27E-02Urea Cycle4.27E-02Arginine Degradation VI (Arginase 2 Pathway)4.27E-02Pentose Phosphate Pathway (Non-oxidative Branch)4.27E-02p38 MAPK Signaling4.47E-02FXR/RXR Activation4.68E-02•[Supplemental Table 1](#s0070){ref-type="sec"} -- Ingenuity Pathway Analysis predicted upstream regulators involved during the PGF2α time-course•[Supplemental Table 2](#s0070){ref-type="sec"} -- Ingenuity Pathway Analysis predicted upstream regulators for the SOMs•[Supplemental Table 3](#s0070){ref-type="sec"} -- Ingenuity Pathway Analysis predicted diseases and functional annotations for the SOMs•[Supplemental Table 4](#s0070){ref-type="sec"} -- Ingenuity Pathway Analysis predicted upstream regulators for the dataset comparison•[Supplemental Table 5](#s0070){ref-type="sec"} -- Ingenuity Pathway Analysis predicted upstream regulators for the genes common to all datasets

2. Experimental design, materials and methods {#s0015}
=============================================

2.1. Animals {#s0020}
------------

Post-pubertal multiparous female cattle (n = 16) of composite breeding (½ Red Angus, Pinzgauer, Red Poll, Hereford and ½ Red Angus and Gelbvieh) were synchronized using two intramuscular injections of PGF2α (25 mg; Lutalyse®, Zoetis Inc., Kalamazoo Michigan, MI) 11 days apart. At mid-cycle (days 9--10), cows were treated with an intra-muscular injection of saline (n = 4) and subjected to a bilateral ovariectomy 0.5 h after the injection.

Cows were also treated with an intra-muscular injection of PGF2α (n = 12) and at each of four time points post-injection (0.5, 1, 2, and 4 h), three cows per time point were subjected to a bilateral ovariectomy through a right flank approach under local anesthesia [@bib4], [@bib5]. The CL was removed from each ovary, weighed and \< 5 mm^3^ sections were snap-frozen in liquid N~2~ for subsequent protein and RNA analysis. Plasma progesterone concentrations were determined using the ImmuChem Progesterone DA Coated Tube radioimmunoassay kit (MP Biomedicals, Santa Ana, CA) with an intra-assay coefficient of variation of 9.13% and inter-assay coefficient of variation of 7.99%. The University of Nebraska-Lincoln Institutional Animal Care and Use Committee approved all procedures and facilities used in this animal experiment and animal procedures were performed in June 2009 (Control, 0.5, and 1 h) or October 2010 (2 and 4 h) at the University of Nebraska---Lincoln, Animal Sciences Department. Statistical differences in animal characteristics were determined using Kruskal-Wallis test followed by Dunn\'s post-test or one-way ANOVA followed by Bonferroni\'s multiple comparison test as appropriate (GraphPad Prism, La Jolla, CA).

2.2. Affymetrix bovine gene chip microarray {#s0025}
-------------------------------------------

Luteal tissue from saline-treated (n = 3), and PGF2α treated animals \[0.5 h (n = 3), 1 h (n = 3), 2 h (n=3), and 4 h (n = 3)\] were homogenized and RNA was extracted using a Stratagene RNA Isolation Kit (Santa Clara, CA) following manufacturer\'s instructions. Transcriptional changes were analyzed by hybridization of 500 ng biotinylated cDNA using Affymetrix (Santa Clara, CA) bovine whole-transcript microarray (Bovine Gene v1 Array \[BovGene-1_0-v1\]; GPL17645) at the University of Nebraska Medical Center Microarray Core Facility. Comprehensive microarray methods and data was deposited in GEO database under accession GSE94069.

2.3. Microarray statistics {#s0030}
--------------------------

The microarray data were preprocessed using the robust multi-array average (RMA) method from Affymetrix expression console software (Affymetrix Inc., Santa Clara, CA) to normalize data at the exon level. The mean intensities of multiple probe sets of the same gene were calculated under each array to obtain the corresponding gene expression intensities. The data was filtered to keep the genes with a raw expression value after preprocessing to be 10 or more for at least three samples. Linear Models for Microarray Analysis (LIMMA) [@bib6] in the Bioconductor suite [@bib7] under the statistical program R [@bib8] was applied to compare the log ratio between each of the PGF2α time points and the saline control after adjusting for the box effect. LIMMA applies a linear model and empirical Bayes method for assessing differential expression of the microarray data. Transcripts with a fold-change of at least 1.5 and a Benjamini-Hochberg adjusted *P*-value of less than 0.05 for each treatment condition versus control were identified as differentially expressed genes.

2.4. Self-organizing maps and statistics {#s0035}
----------------------------------------

Microarray data was filtered to keep genes with a raw expression value after preprocessing to be 30 or more for at least three samples. The log ratio between each of the time points and the saline control were compared using Linear Models of Microarray Analysis in the Bioconductor suite in R. The self-organizing map (SOM) clustering algorithm GeneCluster 2.0 [@bib9] was applied to differentially expressed genes that had a greater than 1.5-fold change in expression and *P*-value ≤ 0.05 between PGF2α-treated samples and the saline control. The mean normalized log~2~ intensity values from each of the five examined biological conditions were used as transcript expression profiles in the clustering analysis. The number of iterations in SOM clustering was set to 500,000 to generate SOMs and hierarchical clustering (correlation-based distance, average link).

2.5. Dataset comparisons {#s0040}
------------------------

Two previously published microarray datasets GSE23348 [@bib2] and GSE27961 [@bib3] examined the effect of *in vivo* PGF2α or analog treatment on the bovine luteal transcriptome using Affymetrix Bovine Whole Genome Gene Chips (GPL 2112). The datasets were chosen for comparison to the transcriptome dataset presented herein based on the use of a similar bovine gene array platform and similarities in the experimental protocol comparing mid-cycle control CL expression profiles to CL profiles after treatment with PGF2α analog for 4 h (GSE23348) or 6 h (GSE27961). Original.CEL and.CHP files were downloaded from the GEO database and processed as described above in the *Statistical Methods*. The differentially expressed mRNAs at 4 or 6 h were compared between the three microarray datasets to determine the similarities among the datasets.

2.6. Pathway analysis {#s0045}
---------------------

Pathway analysis was evaluated using Ingenuity Pathway Analysis (IPA) \[Application: Build: 430520M Copyright 2017 QIAGEN (Redwood City, CA)\]. Transcripts found to be differentially expressed compared to saline-injected controls with \> 1.5-fold change and *P* \< 0.05 were input into IPA, DAVID, Panther, or STRING for bioinformatics analysis using Entrez gene IDs. Differentially expressed transcripts were analyzed in IPA using core analysis followed by comparison analysis between time points, or datasets. Unmapped genes in IPA were as follows: 0.5 h (20.6%), 1 h (8.7%), 2 h (11.7%), 4 h (13.3%), GSE94069 (12.6%, [@bib1]), GSE23348 (9.8%, [@bib2]), GSE27961 (8.0%, [@bib3]) and common genes (6.5%). Data sets were assessed for prediction of upstream regulators and signaling pathways. Additional pathway analysis was completed using DAVID (Version 6.8, released: Oct 2016) [@bib10], [@bib11]; unmapped genes in DAVID were as follows: 0.5 h (0%), 1 h (1%), 2 h (1.7%), 4 h (1.2%), GSE94069 (0.7%, [@bib1]), GSE23348 (0.8%, [@bib2]), GSE27961 (0.7%, [@bib3]) and common genes (no unmapped genes). The Panther database was used for gene annotations and comparison to other bioinformatics tools (Version 11.1, released: Oct 2016) [@bib12], [@bib13], [@bib14]; unmapped genes in Panther were as follows: 0.5 h (34.5%), 1 h (28.2%), 2 h (35.5%), 4 h (38.9%), GSE94069 (39.5%, [@bib1]), GSE23348 (31.6%, [@bib2]), GSE27961 (29%, [@bib3]) and common genes (24.2%). Finally, the STRING Database (Version 10.0, released: Apr 16, 2016) [@bib15] was used to validate IPA findings and provide unique perspectives based on each tool\'s functionality.

Description of the methods are derived from the companion article [@bib1] in Molecular and Cellular Endocrinology.
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[^3]: Original file contains pathways that contain at least one timepoint with \| z-score\| \> 2. Pathways are sorted based on the \|Avg\| z-score from all four time points. \|Avg\| z-score is used solely for sorting of results, only z-scores for individual time points allow determination of pathway activation or inhibition. (B-H) Benjamini-Hockberg Multiple Testing Correction P-value limit set to 0.05

[^4]: Original file contains pathways that contain at least dataset with \| z-score\| \> 2. Pathways are sorted based on the \|Avg\| z-score from all three datasets. \|Avg\| z-score is used solely for sorting of results, only z-scores for individual time points allow determination of pathway activation or inhibition. (B-H) Benjamini-Hockberg Multiple Testing Correction P-value limit set to 0.05

[^5]: Original file has pathways with P-value \> 0.02 and sorted from largest to smallest based on z-score then smallest to largest P-value, Fisher\'s exact test P-value limit set to 0.05
